IFNA1 and pancreatic adenocarcinoma: The phase III CapRI trial compared the outcomes of postoperative cisplatin, IFN α-2b, and 5-FU plus external radiation with those of 5-FU alone among patients with resected pancreatic adenocarcinoma [17].